Andrew D. Zelenetz, MD, PhD
Professor of Medicine, Chair of the Non-Hodgkin’s Lymphoma Panel (NCCN), Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Dr. Zelenetz is Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center in New York. Prior to that, he had held the positions of Vice Chair, Medical informatics from January 2013 to May 2016 and Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-December 2012. He is also Professor of Medicine at Weill Cornell Medical College.
He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.
Dr. Zelenetz received his BA from Harvard College, his PhD from Harvard University’s Graduate School of Arts and Sciences, Division of Medical Sciences and his MD from Harvard Medical School. Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he is Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee, Chair of the NCCN Non-Hodgkin’s Lymphoma Panel, Board Member of the Leukemia and Lymphoma Society and member of the Lymphoma Research Foundation Scientific Advisory Board. He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from the National Comprehensive Cancer Network in 2012.